16 Jan

How Does Rapid Start Up Affect Clinical Trials?

Fast, efficiently run trials benefit from gaining a competitive edge, a good reputation and credibility amongst stakeholders, as well as a period of exclusivity if the product is the first to be introduced to market.

Importantly, a rapid start up ensures that potential treatments reach the patients who need them most as soon as possible.

Recently, PhRMA indicated that a successful drug trial costs around $2.6 billion on average. The cost per day can fall anywhere between $600,000 and $8 million[1].

It makes sense then that the faster these processes can be achieved, the more cost-effective and efficient the trial will be.

 

What is a rapid start up?

‘Rapid start up’ refers to accelerating these processes and strategies to set up a clinical trial as quickly as possible without compromising quality and integrity. This includes expedited regulatory submissions, streamlined ethics processes, and prompt site selection and setup.

In many cases, multiple steps progress simultaneously instead of waiting for one stage to complete before starting on the next.

 

Why the ANZ region is the answer to achieving successful rapid start up

Australia and New Zealand (ANZ) have some of the fastest and most streamlined ethics and regulatory frameworks in the world. This means that the processes surrounding the study start up phase are far simpler than in the US or Europe, for example.

It makes sense then that global sponsors are looking to conduct trials in the ANZ region so that they can save time and money. According to cancer-fighting organisation BeiGene’s Commercial VP and Head of APAC, Adam Roach, the first patient into a clinical trial (after approvals) in Australia is, on average, about three months. In the US or EU, however, it’s six to nine months [2].

ANZ does not require an Investigational New Drug Application (IND), and full Good Manufacturing Practices (GMP) material is not mandated for Phase I clinical trials. Because of this, the regulatory timeline can be shortened by up to a year compared to the US.

Costs associated with regulatory and ethics submissions are also relatively low compared with many other regions.

Despite the speed at which the ANZ achieves start up, all regulatory and ethical processes are of an extremely high standard, ensuring quality trial data. Any clinical data collected in this region is accepted by other major regulatory bodies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

It is also widely accepted that the ANZ region safeguards the interests of the organisations involved, as well as the wellbeing of the end-users.

Not only is ANZ a highly sought-after region to conduct a trial because it is reliable, more cost-effective, streamlined, and simpler, but the first patient will be enrolled faster than anywhere else in the world

 

How can these benefits be leveraged?

Due to the region’s rapid approval process, Australia and New Zealand are especially sought after to run early-phase clinical trials. Early phase studies can be conducted in ANZ while finalising regulatory applications with the FDA and EMA for later phase clinical trials that take place in the US, Europe and China due to these countries’ vast populations.

Using the data collected from earlier approved ANZ trials, parallel submissions can lead to synchronised regulatory approvals in multiple regions.

This is a strategic move that saves a significant amount of time and money

 

The advantages of choosing a local CRO

Wherever you are in the world, choosing a CRO who knows and understands the nuances of the region in which the trial is being conducted is highly beneficial.

Despite ANZ’s relatively straightforward regulatory processes, there are unique regional and cultural requirements that play vital roles in the application process.

Ideally, your chosen CRO should have strong, longstanding relationships with ethics and regulatory body representatives and be fully in touch with changes in the local industry. This would mean that local CROs will usually be notified about the availability for the ethics meetings, which would enable them to align the application submission accordingly, possibly preventing a two- to four-week delay in the entire process.

Harnessing the CRO’s established and trusted relationships with trial sites and local experts is also an invaluable benefit.

 

PharmaSols’ proven track record in successful rapid start up

PharmaSols has a dedicated rapid start up team, consisting of regulatory and clinical professionals with more than 20 years’ of experience in the ANZ clinical trial industry.

This team understands country-specific and regional regulations, enabling us to implement proactive solutions to potential challenges and accelerate the timelines from Trial Site selection to First Patient In.

We have robust relationships with most Trial Sites in Australia and New Zealand. Our knowledge of Trial Site experience, capabilities, facilities and historic performance enables us to complete feasibility and qualification more efficiently. We also offer our clients valuable insight as to which sites are best equipped to deliver excellent results for their study.

As an example, PharmaSols was selected as the local CRO for a US biopharmaceutical organisation that required quick turnaround times for a complex 1b oncology study.

After receiving the protocol, PharmaSols submitted the ethics application to the New Zealand Ethics Committee within one working day.

Post-review, provisional approval was secured in 14 days. Considering the recommendations from the ethics committee, PharmaSols addressed and resubmitted the final application within nine working days. The committee then granted full approval just 20 working days after submission.

In total, PharmaSols efficiently navigated the ethics approval process in New Zealand, securing approval within 55 days of protocol receipt. The process was even faster in Australia; full approval was achieved in just 35 days of receiving the protocol.

Notably, PharmaSols went on to recruit almost twice as many patients as our global CRO partner over the three-month recruitment period.

 

PharmaSols

At PharmaSols, our Rapid Start Up team strategically leverages our advantageous position in the ANZ region. Our proven track record underscores the effectiveness of our approach, emphasising that clinical trials can be swift, efficient, and cost-effective whilst maintaining the highest standards of excellence.

Speak to our Rapid Start Up specialists to accelerate your upcoming study.

 

References

[1] Accelerating Study Start-Up: The Key to Avoiding Trial Delays (Online) Available at: https://acrpnet.org/2017/02/01/accelerating-study-start-up-the-key-to-avoiding-trial-delays/

[2] https://www.smh.com.au/business/entrepreneurship/invest-bravely-cancer-fighting-giant-sets-sights-on-australia-20220429-p5ah8j.html

Other News

How To Prevent Clinical Drug Trial Delays

Delayed clinical drug trials are a thorn in the side of any study stakeholder. This blog will discuss at the main causes of delayed trials, and what precautions can be taken to ensure timelines can be adhered to.

Read more
How Does Rapid Start Up Affect Clinical Trials?

Fast, efficiently run trials benefit from gaining a competitive edge, a good reputation and credibility amongst stakeholders, as well as a period of exclusivity if the product is the first to be introduced to market.

Read more
Ethnicity And Clinical Trials - Where Is the Diversity?

One of the most important aspects of a clinical trial is that it represents a diverse ethnic profile. For a pharmaceutical product to be accepted by international regulatory bodies such as the FDA and the EMA, it is essential that the patient recruitment process places ethnic diversity as a priority.

Read more